Viemed posts record FY2025 revenue $270.3M; net income +33%; guides FY2026 rev $310-320M

VIEMED HEALTHCARE, INC.

Q4 revenue $76.2M (record, +26% YoY); FY revenue $270.3M (record, +21% YoY).
FY2025 net income $14.9M ($0.37 diluted EPS), +33% YoY; adjusted EBITDA record $61.4M.
FY2025 operating cash flow $51.9M; free cash flow $28.1M (more than doubled YoY).
2026 guidance: revenue $310-320M, adjusted EBITDA $65-69M, capex 10-11.5% of revenue.
Board authorized share repurchase of up to 1,930,131 shares (~5% outstanding) through March 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VIEMED HEALTHCARE, INC. reported the three months and year ended December 31, 2025 results: revenue $76.2 million, net income $5.6 million, or $0.14 per diluted share, EPS $0.14 per diluted share. Guidance initiated.

Period: the three months and year ended December 31, 2025
Revenue: $76.2 million
Net income: $5.6 million, or $0.14 per diluted share
EPS: $0.14 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

December 31, 2026. Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD): • Net revenues for the quarter ended December 31, 2025 were a company record $76.2 million, an increase of $15.5 million, or 26%, over net revenues reported for the comparable quarter ended December 31, 2024. Total net revenues for the year ended December 31, 2025 were

View on SEC.gov

Browse all earnings releases →

VIEMED HEALTHCARE, INC. filing history →

Source: SEC EDGAR

accession 0001729149-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.